IL159110A0 - Small molecule antagonists of bcl2 family proteins - Google Patents

Small molecule antagonists of bcl2 family proteins

Info

Publication number
IL159110A0
IL159110A0 IL15911002A IL15911002A IL159110A0 IL 159110 A0 IL159110 A0 IL 159110A0 IL 15911002 A IL15911002 A IL 15911002A IL 15911002 A IL15911002 A IL 15911002A IL 159110 A0 IL159110 A0 IL 159110A0
Authority
IL
Israel
Prior art keywords
bcl
family proteins
small molecule
molecule antagonists
bcl2 family
Prior art date
Application number
IL15911002A
Other languages
English (en)
Original Assignee
Univ Michigan
Univ Georgetown Med Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Univ Georgetown Med Center filed Critical Univ Michigan
Publication of IL159110A0 publication Critical patent/IL159110A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15911002A 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins IL159110A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29398301P 2001-05-30 2001-05-30
US10/158,769 US20030008924A1 (en) 2001-05-30 2002-05-30 Small molecule antagonists of Bcl-2 family proteins
PCT/US2002/017206 WO2002097053A2 (fr) 2001-05-30 2002-05-30 Petits antagonistes moleculaires de proteines de la famille bcl2

Publications (1)

Publication Number Publication Date
IL159110A0 true IL159110A0 (en) 2004-06-01

Family

ID=31495521

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15911002A IL159110A0 (en) 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins

Country Status (18)

Country Link
US (1) US20030008924A1 (fr)
EP (1) EP1474121B1 (fr)
JP (1) JP2005515158A (fr)
KR (1) KR20040108528A (fr)
CN (1) CN1589135A (fr)
AT (1) ATE474568T1 (fr)
AU (1) AU2002305769B2 (fr)
CA (1) CA2449245A1 (fr)
DE (1) DE60237115D1 (fr)
ES (1) ES2349349T3 (fr)
HK (1) HK1071066A1 (fr)
IL (1) IL159110A0 (fr)
MX (1) MXPA03010977A (fr)
NO (1) NO20035301D0 (fr)
NZ (1) NZ529792A (fr)
SG (1) SG157952A1 (fr)
WO (1) WO2002097053A2 (fr)
ZA (1) ZA200309306B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20023357D0 (no) * 2002-04-19 2002-07-11 Amersham Health As Blanding
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
ATE478663T1 (de) * 2003-06-25 2010-09-15 Burnham Inst Analoga von apogossypol zur verwendung in der behandlung von krebs
ZA200607956B (en) * 2004-03-25 2008-02-27 Univ Michigan Gossypol co-crystals and the use thereof
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CN101006065B (zh) 2004-06-17 2012-07-11 英菲尼蒂发现公司 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
CA2600797A1 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Inhibiteurs de chromen-4-one des elements anti-apoptotiques de la famille bcl-2 et utilisations
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
JP2009532354A (ja) * 2006-03-30 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ゴシポール共結晶の生産方法
CA2650520A1 (fr) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Traitement de tumeurs exprimant ras
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) * 2007-04-20 2009-01-29 Clemson University Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (fr) * 2007-09-10 2009-03-19 Curis, Inc. Inhibiteurs de bcl-2
EP2205088B1 (fr) * 2007-10-19 2018-02-21 Burnham Institute for Medical Research Inhibiteurs à base de naphtalène de protéines anti-apoptotiques
EP2323648A4 (fr) * 2008-08-14 2012-10-03 Uab Research Foundation Agents anti-arythmie, procédés pour leur utilisation, procédés pour leur identification et kits pertinents
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
US8937193B2 (en) * 2009-10-08 2015-01-20 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
AU2011279303B2 (en) 2010-07-12 2015-07-16 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US8940737B2 (en) * 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2794592A1 (fr) 2011-12-23 2014-10-29 Novartis AG Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
CA2859869A1 (fr) 2011-12-23 2013-06-27 Novartis Ag Composes inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
WO2013096049A1 (fr) 2011-12-23 2013-06-27 Novartis Ag Composés permettant d'inhiber l'interaction de bcl-2 avec des partenaires de liaison
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
MX2014007732A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015123617A1 (fr) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Procédé pour réduire l'expression du gène bcl2
EP3708170A1 (fr) 2014-05-05 2020-09-16 BioVentures, LLC Compositions et procédés d'inhibition de protéines antiapoptotiques bcl-2 comme agents anti-âge
CA2955972A1 (fr) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions et procedes de depletion selective de cellules senescentes
CN105884634B (zh) * 2015-01-05 2019-06-04 南开大学 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
WO2017027845A1 (fr) 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Dérivés phénylsulfonamido-benzofurane et leur utilisation dans le traitement de maladies prolifératives
WO2017087810A1 (fr) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Procédé de criblage d'inhibiteurs ciblant des voies de survie anti-apoptotiques
CN108697667A (zh) 2016-02-18 2018-10-23 延世大学校产学协力团 用于治疗癌症、含有多酚化合物作为活性成分的药物组合物
WO2017142348A1 (fr) * 2016-02-18 2017-08-24 연세대학교 산학협력단 Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
CN112105360B (zh) 2018-01-22 2024-01-30 生物风险投资有限责任公司 用于癌症治疗的bcl-2蛋白降解剂
WO2019221755A1 (fr) 2018-05-18 2019-11-21 Bioventures, Llc Analogues de piperlongumine et leurs utilisations
CN109876145A (zh) * 2019-04-25 2019-06-14 中国科学院化学研究所 醋酸棉酚和化疗药的联合用药物
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
WO2022133030A1 (fr) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2
AU2022405016A1 (en) 2021-12-09 2024-06-06 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
WO2002097053A2 (fr) 2002-12-05
US20030008924A1 (en) 2003-01-09
JP2005515158A (ja) 2005-05-26
NO20035301D0 (no) 2003-11-28
HK1071066A1 (en) 2005-07-08
NZ529792A (en) 2007-04-27
ATE474568T1 (de) 2010-08-15
KR20040108528A (ko) 2004-12-24
EP1474121A4 (fr) 2006-05-03
DE60237115D1 (de) 2010-09-02
ZA200309306B (fr) 2006-07-26
MXPA03010977A (es) 2005-04-08
WO2002097053A3 (fr) 2004-09-10
EP1474121B1 (fr) 2010-07-21
AU2002305769B2 (en) 2007-07-19
CA2449245A1 (fr) 2002-12-05
ES2349349T3 (es) 2010-12-30
EP1474121A2 (fr) 2004-11-10
SG157952A1 (en) 2010-01-29
CN1589135A (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
IL159110A0 (en) Small molecule antagonists of bcl2 family proteins
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
BR0201714A (pt) Uso de hidroxiflavanonas para encobrir o sabor amargo
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2001098317A3 (fr) Alpha-glycosylceramides destines au traitement d'infections bacteriennes et fongiques
MX2007012623A (es) Inulina de cadena larga.
WO2003038060A3 (fr) Inhibiteurs de petites molecules cibles sur bcl-2
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE60331344D1 (en) Biguanidderivate
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
WO2004081033A3 (fr) Synthese de proteines au moyen d'une expression proteique exempte de cellule
GB0004576D0 (en) Proteins
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
GB2430365B (en) High-purity texaphyrin metal complexes
AU2003259750A8 (en) Methods and compositions for targeting secretory lysosomes
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
MXPA03010821A (es) Composiciones de aroma y fragancias.